GlassScriptPhysician profile
Robert Archer Ross
NPI 1023723715
$4,270.47
in general payments reported to CMS, 2019-2025
29 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,136 · 2024: $1,708 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,270.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $841.79 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $650.45 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $401.90 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $389.62 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $273.35 | 2024-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $186.79 | 2023-2025 | |
| Exact Sciences Corporation | $152.44 | 2023-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $149.60 | 2023 | |
| Cagent Vascular INC | $144.00 | 2025 | Serrantor |
| Amgen INC. | $141.42 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.24 | 2023-2025 | Jardiance, Synjardy |
| Corcept Therapeutics | $116.30 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.50 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $75.17 | 2023-2025 | Nexletol, Nexlizet |
| Astellas Pharma US INC | $71.10 | 2024-2025 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $52.66 | 2025 | Nuplazid |
| Boston Scientific Corporation | $49.41 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Glaxosmithkline, LLC. | $48.69 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $45.55 | 2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $41.35 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Shield Therapeutics INC | $41.27 | 2024 | |
| Abbott Laboratories | $37.99 | 2023-2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $29.55 | 2025 | Hetlioz, Fanapt |
| Organogenesis INC. | $23.92 | 2024 | Affinity |
| Ultragenyx Pharmaceutical INC. | $23.46 | 2023 | |
| Alnylam Pharmaceuticals INC. | $23.26 | 2023 | Givlaari |
| Edwards Lifesciences Corporation | $21.64 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Seqirus USA INC | $20.93 | 2024 | Flucelvax, Fluad |
| C2n Diagnostics, LLC | $16.12 | 2025 | Precivityad2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.